There is an acute shortage of Covid -19 vaccines in India & developing countries. Intradermal use of COVID 19 Vaccines will result in saving up to four fifth (80%) volume of vaccines-i.e. up to five individuals can be vaccinated by ID dose(0.1mL) as against one individual by IM dosage(0.5mL) of the vaccine.
Rabies vaccines (PCECV &PVRV) ordinarily given by IM route were also found to be equally efficacious and safe by ID route as lifesaving in Rabies post – exposure prophylaxis (PEP). Recent studies underlines the feasibility of administering COVID vaccines by ID route and having promising results in mRNA-1273 vaccine[i] and ChAdOx1 Vaccine[ii] (COVISHIELD) as well as ZyCoV-D, a DNA vaccine[iii]. We also expect that intradermal use of COVID vaccines may have lesser systemic side effects like micro cloting events etc.
It is high time we think of doing large scale studies for intradermal use of COVID 19 vaccine world over to save costs, make them available for more people.
Dr. Omesh Bharti, SHimla, India
[i] . Roozen G et al;Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy; https://www.medrxiv.org/content/10.1101/2021.07.27.21261116v1
[ii] . Singhatiraj, E.; Pongpirul, K.; Jongkaewwattana, A.; Hirankarn, N. Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report. Vaccines 2021, 9, 990. https://doi.org/10.3390/vaccines9090990
[iii] . Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India;